Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Yan Qin, Min Feng, Yanyao Wu, Yanling Wang, Xiangcong Zhao, Guangying Liu, Chong Gao, Jing Luo, Hui Guo
Patients with rheumatoid arthritis (RA) are more susceptible to infections, which elevate the levels of relative cytokines. However, the ability of the cytokines levels to predicate bacterial infections in RA patients remains unclear. Here, we assessed the ability of the combination of serum cytokine levels and blood parameters to diagnose bacterial infections in RA patients. We measured the levels of a panel of serum cytokine and blood parameters in 168 RA patients and 81 healthy individuals. RA patients were divided into the bacterial infection (INFE) group (n = 76) and RA flare without INFE group (n = 92)...
August 19, 2020: Cytokine
#22
JOURNAL ARTICLE
Daniele F Pereira, Jamil Natour, Luiza H C Ribeiro, Fernando B M D Ferreira, Artur R C Fernandes, Rita N V Furtado
OBJECTIVES: We aimed to compare the painless synovitis evolution with painful synovitis, based on bone erosion by ultrasonography over a year in women with longstanding rheumatoid arthritis. Ultrasound inflammatory measurements and radiographic, functional and clinical findings were also compared between groups at the end of the same follow-up. METHODS: A prospective cohort study was rolled out, involving 60 women with RA, divided into two groups: painless and painful, with 30 patients in each group...
May 2021: Clinical and Experimental Rheumatology
#23
REVIEW
Claudia Terraza-Aguirre, Mauricio Campos-Mora, Roberto Elizondo-Vega, Rafael A Contreras-López, Patricia Luz-Crawford, Christian Jorgensen, Farida Djouad
Mesenchymal stem cells (MSCs) exhibit potent immunoregulatory abilities by interacting with cells of the adaptive and innate immune system. In vitro, MSCs inhibit the differentiation of T cells into T helper 17 (Th17) cells and repress their proliferation. In vivo, the administration of MSCs to treat various experimental inflammatory and autoimmune diseases, such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, and bowel disease showed promising therapeutic results...
July 10, 2020: Cells
#24
JOURNAL ARTICLE
Fiona Cramp, Rachel Thomas, Anne M Haase, Melissa Domaille, Sarah Manns, Caroline Swales, Judy Hurfurt, Nicola E Walsh
OBJECTIVE(S): The aim of this study is to test the feasibility and acceptability of promoting engagement in physical activity in early rheumatoid arthritis (PEPA-RA) to inform a future trial. DESIGN: A 'proof of concept' study was carried out. SETTING: This study was conducted in community hospitals delivered by musculoskeletal primary care physiotherapists. PARTICIPANTS: Participants were 12 adults with rheumatoid arthritis (RA) diagnosed 6-24 months previously (nine females, three males; mean age 58 years, range 23-79)...
July 14, 2020: Musculoskeletal Care
#25
JOURNAL ARTICLE
Y Zhang, M Peltonen, J C Andersson-Assarsson, P-A Svensson, C Herder, A Rudin, Lms Carlsson, C Maglio
OBJECTIVE: The aim of the current study is to determine whether baseline serum adiponectin levels predict the development of rheumatoid arthritis (RA). METHOD: The current report includes 3693 individuals from the Swedish Obese Subjects (SOS) study. The original SOS study is a longitudinal non-randomized controlled study aiming to assess the effect of bariatric surgery on obesity-related mortality and morbidity. Participants included in the present report had adiponectin measurement available at baseline and no prevalent RA...
July 15, 2020: Scandinavian Journal of Rheumatology
#26
JOURNAL ARTICLE
Fraser C Henderson, Robert Rosenbaum, Malini Narayanan, Myles Koby, Kelly Tuchman, Peter C Rowe, Clair Francomano
Atlanto-axial instability (AAI) is common in the connective tissue disorders, such as rheumatoid arthritis, and increasingly recognized in the heritable disorders of Stickler, Loeys-Dietz, Marfan, Morquio, and Ehlers-Danlos (EDS) syndromes, where it typically presents as a rotary subluxation due to incompetence of the alar ligament. This retrospective, IRB-approved study examines 20 subjects with Fielding type 1 rotary subluxation, characterized by anterior subluxation of the facet on one side, with a normal atlanto-dental interval...
June 2021: Neurosurgical Review
#27
JOURNAL ARTICLE
Leena R Baghdadi
BACKGROUND: The high risk of cardiovascular disease is well recognized in rheumatoid arthritis. Type 2 diabetes also attributes to this increase in risk. Rheumatoid arthritis is a chronic inflammatory condition, which aggravates insulin resistance, placing the patients at a higher risk of type 2 diabetes and subsequent cardiovascular outcomes. Methotrexate treatment, as a gold standard anti-inflammatory drug in the treatment of rheumatoid arthritis has shown beneficial effects on cardiovascular health...
2020: PloS One
#28
JOURNAL ARTICLE
Sin Ngai Ng, Mette B Axelsen, Mikkel Østergaard, Susanne Juhl Pedersen, Iris Eshed, Merete L Hetland, Jakob M Møller, Lene Terslev
Objective: To compare joint inflammation seen by whole-body magnetic resonance imaging (WBMRI), with "whole-body" ultrasound and clinical assessments, in patients with active rheumatoid arthritis (RA) before and during tumor necrosis factor-inhibitor (TNF-I, adalimumab) treatment. Methods: In 18 patients with RA, clinical assessment for joint tenderness and swelling, WBMRI, and ultrasound were obtained at baseline and week 16. Wrist, metacarpophalangeal (MCP) and proximal interphalangeal (PIP), elbow (except for WBMRI), shoulder, knee, ankle, and metatarsophalangeal joints were examined...
2020: Frontiers in Medicine
#29
JOURNAL ARTICLE
Sara Naji Rad, Behnam Rafiee, Gagan Raju, Mahdis Solhjoo, Prachi Anand
Large granular lymphocyte leukemia (LGL) is a clonal, lymphoproliferative disorder with an indolent disease course. T-cell LGL (T-LGL) is the most common type of LGL driven from T-cell lineage (85%). The coexistence of T-LGL with several types of autoimmune disorders, mostly rheumatoid arthritis (RA), has been reported. Felty's syndrome (FS) is defined by splenomegaly, low neutrophil count, and destructive arthritis and is usually seen in <1% of patients with RA. About 30% to 40% of patients with FS have been reported to have an expansion of large granulated lymphocytes in the circulation...
January 2020: Journal of Investigative Medicine High Impact Case Reports
#30
JOURNAL ARTICLE
Pierre-Antoine Juge, Joyce S Lee, Jessica Lau, Leticia Kawano-Dourado, Jorge Rojas Serrano, Marco Sebastiani, Gouri Koduri, Eric Matteson, Karina Bonfiglioli, Marcio Sawamura, Ronaldo Kairalla, Lorenzo Cavagna, Emanuele Bozzalla Cassione, Andreina Manfredi, Mayra Mejia, Pedro Rodríguez-Henriquez, Montserrat I González-Pérez, Ramcés Falfán-Valencia, Ivette Buendia-Roldán, Gloria Pérez-Rubio, Esther Ebstein, Steven Gazal, Raphaël Borie, Sébastien Ottaviani, Caroline Kannengiesser, Benoît Wallaert, Yurdagul Uzunhan, Hilario Nunes, Dominique Valeyre, Nathalie Saidenberg-Kermanac'h, Marie-Christophe Boissier, Lidwine Wemeau-Stervinou, René-Marc Flipo, Sylvain Marchand-Adam, Pascal Richette, Yannick Allanore, Claire Dromer, Marie-Elise Truchetet, Christophe Richez, Thierry Schaeverbeke, Huguette Lioté, Gabriel Thabut, Kevin D Deane, Joshua J Solomon, Tracy Doyle, Jay H Ryu, Ivan Rosas, V Michael Holers, Catherine Boileau, Marie-Pierre Debray, Raphaël Porcher, David A Schwartz, Robert Vassallo, Bruno Crestani, Philippe Dieudé
QUESTION ADDRESSED BY THE STUDY: Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA. Whether MTX exposure increases the risk of ILD in patients with RA is disputed. We aimed to evaluate the association of prior MTX use with development of RA-ILD. METHODS: Through a case-control study design with discovery and international replication samples, we examined the association of MTX exposure with ILD in 410 patients with chronic fibrotic ILD associated with RA (RA-ILD) and 673 patients with RA without ILD...
February 2021: European Respiratory Journal
#31
JOURNAL ARTICLE
Johan Dalén, Karin Luttropp, Axel Svedbom, Christopher M Black, Sumesh Kachroo
INTRODUCTION: Subsequent lines of subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment may be well motivated in the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)-collectively named inflammatory arthritis (IA). However, the costs associated with switching SC-TNFis are largely unknown. The objective of this retrospective observational study was to explore costs of healthcare resource utilization (HCRU) associated with switching SC-TNFi treatment among biologic-naïve Swedish patients with IA...
July 9, 2020: Advances in Therapy
#32
JOURNAL ARTICLE
Josh Colls, Yvonne C Lee, Chang Xu, Cassandra Corrigan, Fengxin Lu, Georgia Marquez-Grap, Meredith Murray, Dong H Suh, Daniel H Solomon
OBJECTIVES: Electronic patient-reported outcomes (ePROs) transmitted digitally allow patients to communicate with their clinicians and track the activity of chronic diseases, such as RA. Several ePRO smartphone apps have been developed in rheumatology, yet few data have been reported regarding patient adherence. We developed a PRO app for RA and assessed adherence over 6 months. METHODS: We developed an app to deliver daily assessments to participants (RA App v...
January 5, 2021: Rheumatology
#33
JOURNAL ARTICLE
Jorge Monserrat, Cristina Bohórquez, Ana María Gómez Lahoz, Atusa Movasat, Ana Pérez, Lucía Ruíz, David Díaz, Luis Chara, Ana Isabel Sánchez, Fernando Albarrán, Ignacio Sanz, Melchor Álvarez-Mon
Patients with long-term, treated, rheumatoid arthritis (RA) show abnormalities in their circulating CD4+ T-lymphocytes, but whether this occurs in recently diagnosed naïve patients to disease-modifying drugs (DMARDs) is under discussion. These patients show heterogeneous clinical response to methotrexate (MTX) treatment. We have examined the count of circulating CD4+ T-lymphocytes, and their naïve (TN ), central memory (TCM ), effector memory (TEM ) and effector (TE ) subsets, CD28 expression and Vβ TCR repertoire distribution by polychromatic flow cytometry in a population of 68 DMARD-naïve recently diagnosed RA patients, before and after 3 and 6 months of MTX treatment...
August 10, 2019: Cells
#34
JOURNAL ARTICLE
Josef S Smolen, Robert B M Landewé, Johannes W J Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B McInnes, Alexandre Sepriano, Ronald F van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, John Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Mario Humberto Cardiel, Diederik De Cock, Catalin Codreanu, Maurizio Cutolo, Christopher John Edwards, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques-Eric Gottenberg, Merete Lund Hetland, Tom W J Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller-Ladner, Eduardo F Mysler, Jose A P da Silva, Gyula Poór, Janet E Pope, Andrea Rubbert-Roth, Adeline Ruyssen-Witrand, Kenneth G Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde
OBJECTIVES: To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field. METHODS: An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature searches on efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) since the last update (2016) until 2019...
June 2020: Annals of the Rheumatic Diseases
#35
RANDOMIZED CONTROLLED TRIAL
Danielle M Gerlag, Mary Safy, Karen I Maijer, Man Wai Tang, Sander W Tas, Mirian J F Starmans-Kool, Astrid van Tubergen, Matthijs Janssen, Maria de Hair, Monika Hansson, Niek de Vries, Aeilko H Zwinderman, Paul P Tak
OBJECTIVES: We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis development. METHODS: Individuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double-blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo...
February 2019: Annals of the Rheumatic Diseases
#36
JOURNAL ARTICLE
Cédric Lukas, Julia Mary, Michel Debandt, Claire Daïen, Jacques Morel, Alain Cantagrel, Bruno Fautrel, Bernard Combe
BACKGROUND AND OBJECTIVE: Early seronegative rheumatoid arthritis (RA) is considered a specific entity, especially regarding diagnostic issues and prognosis. Little is known about its potentially different initial clinical presentation and outcome. We aimed to determine predictors of good response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in seronegative RA patients with early inflammatory arthritis. PATIENTS AND METHODS: Patients from the ESPOIR cohort with early inflammatory arthritis fulfilling the 2010 ACR/EULAR classification criteria for RA despite negativity for both rheumatoid factor and anti-CCP antibodies...
November 15, 2019: Arthritis Research & Therapy
#37
REVIEW
Martina Biggioggero, Andrea Becciolini, Chiara Crotti, Elena Agape, Ennio Giulio Favalli
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by joint involvement, extra-articular manifestations, comorbidities, and increased mortality. In the last few decades, the management of RA has been dramatically improved by the introduction of a treat-to-target approach aiming to prevent joint damage progression. Moreover, the increasing knowledge about disease pathogenesis allowed the development of a new drug class of biologic agents targeted on immune cells and proinflammatory cytokines involved in RA network...
2019: Drugs in Context
#38
REVIEW
Adam Kemeny-Beke, Peter Szodoray
PURPOSE: Our aim was to summarize key aspects of the pathomechanism and the ocular involvements of rheumatic and systemic autoimmune diseases. METHODS: Apart from a paper in French (Morax V, Ann Oculist 109:368-370, 1893), all papers referred to in this article were published in English. All the materials were peer-reviewed full-text papers, letters, reviews, or book chapters obtained through a literature search of the PubMed database using the keywords ocular manifestations; pathogenesis; systemic inflammatory rheumatic diseases; rheumatoid arthritis; osteoarthritis; fibromyalgia; systemic lupus erythematosus; seronegative spondyloarthritis; ankylosing spondylitis; reactive arthritis; enteropathic arthritis; psoriatic arthritis; systemic sclerosis; polymyalgia rheumatica and covering all years available...
February 2020: International Ophthalmology
#39
COMPARATIVE STUDY
Alexandre Virone, Jean-Philippe Bastard, Soraya Fellahi, Jacqueline Capeau, Stéphanie Rouanet, Jean Sibilia, Philippe Ravaud, Francis Berenbaum, Jacques-Eric Gottenberg, Jérémie Sellam
Background: To comparatively investigate the differential effect of second-line tumour necrosis factor inhibitors (TNFis) versus other biological agents on cardiovascular disease (CVD) risk-associated biomarkers in patients with rheumatoid arthritis (RA). Methods: We evaluated the serum levels of lipoprotein-associated apoproteins ApoA1 and ApoB100 and lipoprotein(a) (Lp(a)) and the leptin/adiponectin ratio (LAR) as an insulin resistance proxy in patients with RA from the Rotation Or Change (ROC) trial treated with either a second-line TNFi or another biologic (tocilizumab (TCZ), rituximab or abatacept) at baseline and week 24...
2019: RMD Open
#40
RANDOMIZED CONTROLLED TRIAL
Sophie Glatt, Peter C Taylor, Iain B McInnes, Georg Schett, Robert Landewé, Dominique Baeten, Lucian Ionescu, Foteini Strimenopoulou, Mark I L Watling, Stevan Shaw
OBJECTIVE: Evaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) and inadequate response (IR) to certolizumab pegol. METHODS: During this phase 2a, double-blind, proof-of-concept (PoC) study (NCT02430909), patients with moderate-to-severe RA received open-label CZP 400 mg at Weeks 0, 2 and 4, and 200 mg at Week 6...
August 2019: Annals of the Rheumatic Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
